Article Text

Download PDFPDF
153 The PHQ-9 as a tool to measure depression in people with multiple sclerosis
  1. Suzanne Quigley1,2,3,
  2. Emily Beswick1,2,
  3. Pamela Macdonald1,2,
  4. Peter Connick1,2,3
  1. 1Anne Rowling Regenerative Neurology Clinic
  2. 2Centre for Clinical Brain Sciences, University of Edinburgh
  3. 3NHS Lothian


Background Depression has a point prevalence of 25% and lifetime prevalence of 50% in people with MS (pwMS). Due to its convenience, the PHQ9 may be a useful tool in clinical practice for screening and monitoring of depression in pwMS

Objectives To evaluate the internal and external reliability of the PHQ-9 measure of depressive symptoms in people with MS. Secondary objectives are; to evaluate the validity of the PHQ-9 as a measure of depressive symptoms in people with MS and to evaluate the acceptability of the PHQ-9 to people with MS

Design: A cross section validation study

Subjects: People with Multiple Sclerosis

Methods People with MS were recruited from the Rowling Care registry at the Anne Rowling Regenerative Neurology Clinic. Participants complete three questionnaires during a 4 week period using online questionnaires. Statistical analysis will be performed at the end of the study using R Studio

Results The study is ongoing and now in the follow up phase. Provisional results are based on 92 completed participant datasets- Internal reliability of the PHQ-9 using Cronbach’s Alpha was 0.88. External reliability of the PHQ-9 using intraclass coefficient was 0.72.

Conclusions Final conclusions are pending due to ongoing data collection.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.